(Q38349757)

2 September 2017

1 reference

title

Anti-inflammatory therapies for atherosclerosis (English)

1 reference

2 September 2017

0 references

1 reference

1

Magnus Bäck

1 reference

2 September 2017

Göran K Hansson

2

1 reference

2 September 2017

language of work or name

English

0 references

publication date

10 February 2015

1 reference

Nature Reviews Cardiology

2 September 2017

published in

1 reference

2 September 2017

volume

12

1 reference

2 September 2017

issue

4

1 reference

2 September 2017

page(s)

199-211

1 reference

Inflammation, atherosclerosis, and coronary artery disease

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Progress and challenges in translating the biology of atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Inflammation and atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Low density lipoprotein undergoes oxidative modification in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Reduction of atherosclerosis in mice by inhibition of CD40 signalling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

The immune system in atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Sirolimus for the Prevention of In-Stent Restenosis in a Coronary Artery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Colchicine for secondary prevention of cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Colchicine: its mechanism of action and efficacy in crystal-induced inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Gout-associated uric acid crystals activate the NALP3 inflammasome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Impact of allopurinol on risk of myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Low-dose colchicine for secondary prevention of cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Serum uric acid levels predict the severity and morphology of coronary atherosclerosis detected by multidetector computed tomography.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Xanthine oxidoreductase is involved in macrophage foam cell formation and atherosclerosis development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Interleukin-12 is associated with arterial stiffness in healthy individuals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Interleukin-23 serum levels in patients affected by peripheral arterial disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Transforming growth factor-β signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Chemokines: established and novel targets in atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Phospholipase A2 structure/function, mechanism, and signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Phospholipase A2 enzymes and the risk of atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Group X secreted phospholipase A2 limits the development of atherosclerosis in LDL receptor-null mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Thromboxane synthase expression and thromboxane A2 production in the atherosclerotic lesion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Effects of the dual TP receptor antagonist and thromboxane synthase inhibitor EV-077 on human endothelial and vascular smooth muscle cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Altered reactivity to norepinephrine through COX-2 induction by vascular injury in hypercholesterolemic rabbits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Targeted deletions of cyclooxygenase-2 and atherogenesis in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Cyclooxygenase-2 in endothelial and vascular smooth muscle cells restrains atherogenesis in hyperlipidemic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Leukotriene receptors in atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Upregulation of the 5-lipoxygenase pathway in human aortic valves correlates with severity of stenosis and leads to leukotriene-induced effects on valvular myofibroblasts.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Biomechanical factors in the biology of aortic wall and aortic valve diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Biomechanical factors in atherosclerosis: mechanisms and clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Has our understanding of calcification in human coronary atherosclerosis progressed?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Differential leukotriene constrictor responses in human atherosclerotic coronary arteries

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Sulfido-peptide leukotrienes in coronary heart disease - relationship with disease instability and myocardial ischaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Inflammatory mediators in saliva associated with arterial stiffness and subclinical atherosclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Leukotriene B4 pathway activation and atherosclerosis in obstructive sleep apnea.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Inhibitors of the 5-lipoxygenase pathway in atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Multidrug resistance protein-1 affects oxidative stress, endothelial dysfunction, and atherogenesis via leukotriene C4 export

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

The effect of montelukast and low-dose theophylline on cardiovascular disease risk factors in asthmatics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

NOD2-mediated innate immune signaling regulates the eicosanoids in atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Evidence for markers of hypoxia and apoptosis in explanted human carotid atherosclerotic plaques.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Inhibition of the p38 MAP kinase in vivo improves number and functional activity of vasculogenic cells and reduces atherosclerotic disease progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide uptake in a mouse model of atherosclerosis: MRI assessment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Therapeutic potential of p38 MAP kinase inhibition in the management of cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Inhibition of p38 Mitogen-Activated Protein Kinase Reduces Inflammation After Coronary Vascular Injury in Humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Could Direct Inhibition of Inflammation Be the “Next Big Thing” in Treating Atherosclerosis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

The Study Of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): Design and rationale

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Statins exert endothelial atheroprotective effects via the KLF2 transcription factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Induction of the cytoprotective enzyme heme oxygenase-1 by statins is enhanced in vascular endothelium exposed to laminar shear stress and impaired by disturbed flow

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Shear stress sustains atheroprotective endothelial KLF2 expression more potently than statins through mRNA stabilization.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Superoxide production and expression of nox family proteins in human atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Role for Nox1 NADPH oxidase in atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/- mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

NADPH Oxidase 1 Plays a Key Role in Diabetes Mellitus–Accelerated Atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Pharmacological inhibition of NOX reduces atherosclerotic lesions, vascular ROS and immune-inflammatory responses in diabetic Apoe(-/-) mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Coronary stent restenosis in patients treated with cilostazol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Phosphodiesterase-4 inhibitor therapy for lung diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Cardiovascular safety in patients receiving roflumilast for the treatment of COPD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Sildenafil restores endothelial function in the apolipoprotein E knockout mouse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Increased expression of heat shock protein 65 coincides with a population of infiltrating T lymphocytes in atherosclerotic lesions of rabbits specifically responding to heat shock protein 65

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

T cell-based therapies for atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Vaccine for atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Measles virus nucleoprotein induces a regulatory immune response and reduces atherosclerosis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Mycobacterium bovis BCG killed by extended freeze-drying induces an immunoregulatory profile and protects against atherosclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.5

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.

31 March 2020

1 reference

12 December 2020

Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis

1 reference

12 December 2020

Anti-atherosclerotic effect of cilostazol in apolipoprotein-E knockout mice

1 reference

12 December 2020

Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRCARDIO.2015.5

1 reference

2 September 2017

1 reference